Picture: Syncona Ltd

From Novartis to Syncona

London-based Syncona Ltd announces the appointment of Danny Bar-Zohar as Syncona Partner, starting mid of April.

Bar-Zohar studied medicine at the Sackler Faculty of Medicine, Tel-Aviv University (Israel). After that he practiced as general surgery at Tel-Aviv Sourasky Medical Center. He changed to Teva Pharmaceutical and headed multiple therapy areas and clinical programmes in Neurology. Seven years later, he started at Novartis. There, he held multiple roles including Global Head of Neuroscience Development and Chief Scientific Officer of Novartis Pharma Italy. Most recently, he was Global Head of Clinical Development and Analytics, leading all late-stage clinical development across neuroscience, immunology, oncology and ophthalmology.

Syncona is focused on founding, building and funding companies in healthcare and life sciences. The company is listed on the London Stock Exchange.